Exagen ROCE

Mitä Exagen tekee? Exagen Inc is a leading company in the development and marketing of diagnostic tests and precision medicine products. The company was founded in 2001 and is headquartered in Albuquerque, New Mexico, USA. Exagen aims to improve the diagnosis and treatment of autoimmune diseases such as lupus, rheumatism, and similar conditions. The company's history dates back to the discovery of a molecular biomarker associated with rheumatoid arthritis. Based on this biomarker, Exagen developed a diagnostic test called Vectra DA, which determines disease activity in patients with rheumatoid arthritis. The Vectra DA test is the world's first diagnostic test to use this biomarker to determine rheumatism activity with higher accuracy. It was approved by the FDA in 2010 and has since become an important test in the diagnosis and treatment of rheumatism. Exagen has since expanded its business activities to other autoimmune diseases, including systemic lupus erythematosus (SLE) and Sjögren's syndrome. The company offers a range of diagnostic tests, including the AVISE SLE test, AVISE Sjögren's syndrome test, and AVISE lupus test. These tests are designed to increase accuracy in the diagnosis and treatment of autoimmune diseases. The tests are based on a combination of biomarkers specifically selected for each disease. Exagen's tests are used by physicians, clinics, and hospitals to diagnose, monitor, and treat autoimmune diseases. Additionally, the company is also utilized by medical researchers, pharmaceutical companies, and biotechnology companies to support their research and development of therapies against autoimmune diseases. An important aspect of Exagen's business model is collaboration with health insurance companies and healthcare systems. The company works closely with these partners to ensure that its tests are covered by insurance and that patients have access to the best treatment options. In recent years, the company has experienced rapid growth, with a revenue growth of 273% between 2018 and 2020. Exagen's growth has been driven by the introduction of new tests and expansion into new markets. In 2019, the company opened a branch in Germany and expanded its offerings to include the use of digital technologies to support the diagnosis and treatment of autoimmune diseases. Exagen's product portfolio also includes products that support patients in monitoring their autoimmune diseases. This includes the MyRA app and MyRA monitor, which provide real-time information about the health status of rheumatism patients. The app was developed to assist patients in documenting symptoms and monitoring their therapeutic progress. Exagen is an innovative company that aims to improve the diagnosis and treatment of autoimmune diseases. With its advanced diagnostic tests and precision medicine products, the company has already made a significant contribution to healthcare and will continue to play an important role in the future. Exagen on yksi Eurpooliin suosituimmista yhtiöistä.